Omeprazole-d3 (sodium)

Omeprazole-d3 sodium is deuterated labeled Omeprazole (HY-B0113) . Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) [3].

Product Specifications

Product Name Alternative

H 16868-d3 (sodium)

UNSPSC

12352005

Target

Autophagy; Bacterial; Isotope-Labeled Compounds; Phospholipase; Proton Pump

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Autophagy; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Others

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Cancer; Infection; Metabolic Disease

Solubility

10 mM in DMSO

Smiles

O=S(C1=NC2=C([2H])C(OC)=C([2H])C([2H])=C2N1[Na])CC3=NC=C(C)C(OC)=C3C

Molecular Formula

C17H15D3N3NaO3S

Molecular Weight

370.42

References & Citations

[1]Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35 (1) :1322-1330.|[2]Li XQ, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32 (8) :821-7.|[3]Jonkers D, et al. Omeprazole inhibits growth of gram-positive and gram-negative bacteria including Helicobacter pylori in vitro. J Antimicrob Chemother. 1996 Jan;37 (1) :145-50.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.